Case Report

Atypical Fascioliasis; Retreatment Considerations and Feasibility of Structured Remote Follow-Up: A Case Report

Abstract

This case report describes an atypical presentation of fascioliasis in a left-behind child from Yunnan, China in April 2025. The case highlights the combination of atypical hepatic imaging findings, persistent post-treatment eosinophilia, and structured remote follow-up in a single pediatric patient. The child presented with intermittent right-upper-quadrant pain. Abdominal computed tomography revealed multiple patchy low-density lesions in the right hepatic lobe without the characteristic “tunnel sign” but with biliary dilation, a pattern consistent with chronic-stage pediatric fascioliasis reported previously. A clear history of drinking untreated stream water and consuming uncooked wild vegetables was documented. Laboratory tests showed marked eosinophilia (33%), and the diagnosis was confirmed by stool examination and serology. After standard initial treatment with triclabendazole, symptoms persisted with an eosinophil count of 17%. Based on the combination of persistent symptoms and sustained eosinophilia, a decision for retreatment was made. An eosinophil proportion >10% was used as a clinical reference in this case, but this is only a preliminary observation and not a validated criterion. Retreatment was administered, and the patient was monitored through a structured telephone follow-up schedule. Following retreatment, symptoms resolved rapidly, eosinophil levels normalized, imaging lesions resolved by 3 months, and clinical cure was achieved by 6 months. This report illustrates the diagnostic and therapeutic challenges of atypical pediatric fascioliasis and provides preliminary, case-based observations on the possible role of eosinophil-guided retreatment and remote follow-up. These findings should be interpreted cautiously and are not intended to establish a standardized management strategy.

1. Huang L, Li F, Su H, Luo J, Gu W. Emerging human fascioliasis: a retrospective study of epidemiological findings in Dali, Yunnan Province, China (2012-2021). Med Sci Monit. 2023; 29:e940581.
2. Hosseinpour Aghaei B, Taiefi Nasrabadi N, Pirali Y, Shojaei SS. The prevalence of Fasciola (Digenea: Fasciolidae) species in livestock and humans in Iran, a systematic review. Arch Razi Inst. 2025; 80(1):263-9.
3. Girma A, Belete Y, Afework S, Bisrat T. The liver's hidden foe: a case study on human fascioliasis. IDCases. 2024; 37:e02045.
4. Zhang X, Suolang L, Ren Y, et al. Can contrast-enhanced ultrasound differentiate the type of hepatic echinococcosis: cystic echinococcosis or alveolar echinococcosis? Parasit Vectors. 2023; 16:131.
5. Gandhi P, Schmitt EK, Chen CW, Samantray S, Venishetty VK, Hughes D. Triclabendazole in the treatment of human fascioliasis: a review. Trans R Soc Trop Med Hyg. 2019; 113(12):797-804.
6. World Health Organization. Foodborne trematode infections. 2021. https://www.who.int/news-room/fact-sheets/detail/foodborne-trematode-infections
7. Macías Saint-Gerons D, Rodovalho S, Barros Dias ÁL, et al. Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth. Malar J. 2022; 21(1):28.
8. Tilahun M, Adane L, Arega G, Tilahun M. Abdominal CT scan findings of a child with hepatic fascioliasis: a case report on rarely reported emerging disease. Radiol Case Rep. 2025; 20(4):2180-3.
9. De NV, Le TH, Agramunt VH, Mas-Coma S. Early postnatal and preschool-age infection by Fasciola spp.: report of five cases from Vietnam and worldwide review. Am J Trop Med Hyg. 2020; 103(4):1578-89.
10. Ali MH, Hossain MS, Labony SS, et al. Conventional and advanced methods used for the diagnosis of fascioliasis, a food-borne zoonotic disease. J Parasitol Res. 2025; 2025:1353367.
11. Behzadifar M, Bragazzi NL, Behzadifar M, et al. Human fasciolosis in Iran: a meta-analysis study. Infect Disord Drug Targets. 2019; 19(3):258-63.
12. Arga G, Demirol A, Bako D. Fasciola hepatica: the difficult process from clinical suspicion to diagnosis, from diagnosis to treatment. Pediatr Infect Dis J. 2025; 44(7):e272.
13. Akiyoshi K, Kokubo-Tanaka M, Yamauchi S, et al. Fasciolosis reinfection in Japan. Intern Med. 2026;65(6):921-925.
14. Ibrahim N, Abdel Khalek EM, Makhlouf NA, et al. Clinical characteristics of human fascioliasis in Egypt. Sci Rep. 2023; 13(1):16254.
15. Ergenc Z, Kepenekli E, Yakut N, et al. Successful treatment of Fasciola hepatica with metronidazole in a child: a case report. Iran J Parasitol. 2022; 17(4):596-8.
Files
IssueVol 21 No 4 (2026) QRcode
SectionCase Report(s)
Keywords
Atypical fascioliasis Left-behind children Eosinophilia Retreatment decision Remote follow-up

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Liu W, Yang Z. Atypical Fascioliasis; Retreatment Considerations and Feasibility of Structured Remote Follow-Up: A Case Report. Iran J Parasitol. 2026;21(4):571-575.